CN
Latest stock price:
XLifes once again named “top 50 biotechnology enterprises” of GAB
Time:2019-10-17  

Source: Guangdong Medical Valley

On October 16, the second award ceremony for the top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "(GBA")was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as XLifes"), a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., has won the award for the second consecutive year. 

手机上的时时彩怎么玩 The purpose of the award is to promote integration of production, learning and research, discover biotechnology unicorns, and identify leaders of the biotechnology industry in the GBA. The top 50 enterprises include enterprises in medical devices, biopharmaceuticals (including biotherapy, cell therapy, gene therapy) and medical services (including mobile medicine, pension service, physical examination center, etc.).

The panel for the award composed of experts from government agencies, research institutions, investment institutions, medical institutions, etc. After comprehensive evaluation of the technological innovation and future development prospect of the runner up enterprises through field visits and face-to-face discussions with the enterprises. 

 
【About Xiangxue Life Sciences, Ltd】

Xiangxue Life Sciences, Ltd (“XLifes“) is a biomedical company focusing on TCR-based therapies for cancer. Our main technological platform is TCR Affinity Enhanced Specific T-cells (TAEST).

手机上的时时彩怎么玩 The product is a kind of affinity optimized TCR engineered T cells (3rd generation TCR-T). With its enhanced TCR affinity, TAEST targets specifically the intracellular and extracellular tumor antigens and exhibits encouraging clinical efficacy and safety profile. In addition, it has longer in vivo persistency and good therapeutic effects in solid tumors.

We have obtained the investigational new drug (IND) approval for our product TAEST16001 from the NMPA in March 2019, and now we are in the progress of recruiting patients. This is the first TCR-T cell therapy IND approved by the NMPA in China.
XPH Group
XLifeSc
Pharmaceutical
TCM Resources